Plasma homocysteine levels in patients with esophageal cancer

Year 2007, Volume: 14 Issue: 2, 1 - 6, 30.04.2009

Ömer Yılmaz Atila Türkyılmaz Kerim Çayır Atilla Eroğlu Nurettin Karaoğlanoğlu Arif Yılmaz

Abstract

SüleymanDemirel Üniversitesi
TIP FAKÜLTESİ DERGİSİ: 2007 Haziran; 14(2)










Plasma homocysteine levels in patients with esophageal cancer



Omer Yilmaz*, Atila Turkyilmaz**, Kerim Cayir*, Atilla Eroglu**, Nurettin Karaoglanoglu**, Arif Yilmaz*



*Departments of Gastroenterology, Faculty of Medicine, Ataturk University, Erzurum, Turkey

**Departments of Thoracic Surgery, Faculty of Medicine, Ataturk University, Erzurum, Turkey





Özet



Özofagus kanserli hastalarda plazma homosistein düzeyleri



Amaç: Kanser tüm dünyada en önemli sağlık problemlerinden birini oluşturmaktadır. Ölüme neden olan hastalıklar arasında kalp hastalıklarından sonra ikinci sırayı almaktadır. Tümör belirteçleri kanserlerin tanısında ve tedaviye cevabın değerlendirilmesinde kullanılmasına rağmen henüz herhangi bir kanser türü için özgül bir belirteç bulunamamıştır. Hiperhomosisteinemi bir çok hastalıkla ilişkili bulunmuştur. Yapılan değişik çalışmalarda bazı kanser türlerinde de artış tespit edilmiştir. Bu çalışmada özofagus kanserli hastalarda homosistein düzeyleri ve diğer tümör belirteçleri arasındaki ilişki araştırıldı. Methods: Bu çalışmaya 2003 0cak ve 2004 Temmuz tarihleri arasında hastanemizde endoskopik biopsilerle histopatolojik tanısı konmuş toplam 40 özofagus kanserli hasta grubu ile 40 sağlıklı kişiden oluşan kontrol grubu alındı. Tümör belirteçlerinden Homosistein, CEA ve CA19-9 düzeyleri özefagus kanserli hastalar ile sağlıklı kontrol grubu olmak üzere iki grup üzerinde çalışıldı. Veriler istatistiksel olarak karşılaştırılarak özofagus kanserli olgularda homosistein seviyesinin önemi araştırıldı. Bulgular: Kontrol grubu ile kıyaslandığında özofagus kanserli hastalarda plazma homosistein (hcy) düzeyleri anlamlı derecede yüksek bulundu (p<0.05). Yine aynı vakalarda çalışılan tümör belirteçlerinde gözlenen artış kontrol grubu ile kıyaslandığında istatistiksel açıdan anlamlı değildi. Bununla birlikte özofagus kanserli hasta grubunda hcy düzeyleri ile tümör belirteçlerinin düzeyleri arasında herhangi bir korelasyon yoktu. Sonuçlar: Plazma homosistein düzeyleri özofagus kanserlerinde artmaktadır ve tümör belirteci olarak kullanılabileceğini düşünüyoruz. Ancak daha geniş kapsamlı çalışmalara ihtiyaç vardır.



Anahtar kelimeler: Homosistein (hcy), GİS maligniteleri, tümör belirteçleri.





Abstract





Objectives: Cancer accounts for one of the most important health problems in the whole world. Among fatal diseases, it is ranked second following cardiovascular diseases. Though tumor markers are used in the diagnosis of cancers and response to treatment, yet no marker specific to a type of cancer has been found. Hyperhomocysteinemia has been found to be related to several diseases. In various studies conducted, increments in plasma homocysteine have been observed in some cancer types. In this study, the relationship between homocysteine levels and other tumor markers in esophagus cancer patients was investigated.

Methods: A total of 40 patients with esophagus cancer, diagnosed histopathologically with endoscopic biopsies in our clinic, and 40 healthy subjects enrolled in this study. The levels of tumor markers homocysteine, CEA and CA19-9 were investigated in the two groups, namely the esophagus cancer patients and healthy controls. The significance of homocysteine levels in esophagus cancer patients was studied via statistical comparison of the data. Results: As compared with the controls, the plasma homocysteine levels were significantly higher in esophagus cancer patients (p<0.05). The increments observed in other tumor markers studied in the same cases were not statistically significant when compared with the controls. However, no correlation was found between the homocysteine and other tumor marker levels in the esophagus cancer patients. Conclusion: Plasma homocysteine levels increase in esophageal cancers and thus it may possibly be used as a tumor marker. However, further large-scale studies are required for this hypothesis.



Key words: Homocysteine, esophageal carcinoma, tumor markers

Keywords

Homosistein (hcy), GÝS maligniteleri, tümör belirteçleri

References

• Kadayifci A, Benekli M, Savas C. Tumor Belirleyicileri. Turkiye Tip Dergisi 1994; 1: 273- 284.
• Hergenc G, Sahin H. Kanser taný ve prognozunda tümör belirteçlerinin önemi. Sendrom 1994; 4: 50-5.
• Maxwell P. Carcinoembriyonic antigen: Cell adhesion molecule and useful diagnostic marker. Br J Biomed Sci 1999; 56: 209-14.
• Prasad K. Homocystein a risk factor for cardiovaskular disease. Int J Angiology 1999; 8: 76-86.
• Ramussen K, Moller J. Total homocysteine measurament in clinical practice. Ann Clin Biochem 2000; 37 (5): 627-648.
• Ueland PM, Refsum H. Plasma homosysteine a risk factor for vascular disease; plasma levels in health.disease and drug therapy. J Lab Clin Med 1989; 114: 473-501.
• Finkelstein JD. Homocysteine: A history in proress. Nutrition Rewiews 2000; 58 (7): 193-204.
• Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high- performance liquid chromatography with fluorescence detection. 1987;422:43-52.
• Tasan G, Avsar E. Esophageal tumors. In Özden A, Þahin B, Yýlmaz U, Soykan Ý. Eds. Gastroenteroloji. Ankara: Türk Gastroenteroloji Vakfý, 2002: 61-66.
• Fiscbach W, Ritter P. How are tumor markers used in diagnosis and in after-care of gastrointestinal cancers ? Results of nation-wide German survey. Med Clin 1992; 87: 576-9
• Stamm EB, Reynolds RD. Plasma total homocystine may not be the most appropriate index for cardiovascular disease risk. J Nutr 1999; 129:1927-1930.
• Schneede J, Refsum H, Ueland PM. Biological and enviromental determinants of plasma homocysteine. Semin Thromb Hemost 2000; 26: 263-79.
• Welch GN, Loscalzo J. Homocysteine and atherothrombosis. New Eng J Med 1998; 338: 1042-1050.
• Nicoletta B, Maria GA, Samanta M, et al. Genetic polymorphisms in folate and homocysteine metabolism as risk factors for DNA damage. Eur J Human Genetics 2003; 11: 671-678.
• Loscalzo J. The oxidant stress of hyperhomocysteinaemia. J Clin Invest 1996; 98: 5-7.
• Shinji O, Katsuhiko M, Shousuke K. Oxidative damage to cellular and isolated DNA by homocysteine: implications for carcinogenesis. Oncogene 2003; 22: 3530-3538
• Lily LW, James TW. Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker. Clinica Chimica Acta 2002; 322: 21-28.
• Refsum H, Wesenberb F, Ueland PM. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991; 51: 828-35
• Chien-Feng S, Thomas RH, Tsu-Lan W, et al. Serum total homocysteine increases with the rapid proliferation rate of tumor cells and decline upon cell death: a potential new tumor marker. Clinica Chimica Acta 2002; 321: 55-62.
• Glynn SA, Albanes D, Pietinenn P, et al. Colorectal cancer and folate status: a nested case-control study among male smokers. Cancer Epi Bio Prev 1996; 5: 487-494
• Martinez J, Stampfer MJ, Giovannucci E, et al. Methylenetetrahydrofolate reductase polymorphizm, dietary interactions, and risk of colorectal cancer. Cancer Res 1997; 57: 1098- 1102
• Miguel A.M, Jose LU, Maria IA. Role of homocysteine in cell metabolism. Eur J Biochem (2001); 268: 3871-3882
• Maria FP, Sonia A, Mario FF, et al. Germ-Line Variants in Methyl-Group Metabolism Genes and Susceptibility to DNA methylation in Normal Tissues and Human Primary Tumors. Cancer Research 2002; 62: 4519-4524.
• Chern CL, Huang RF, Chen YH, et al. Folate deficiency-induced oxidative stres and apoptosis are mediated via homocysteine-dependent overproduction of hydrogen peroxide and enhanced activation of NF-kappaB in human HepG2 cells. Biomed Pharmacother 2001; 55 (8): 434-42.